NCT03209492View on ClinicalTrials.gov

"Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for Prostate Cancer"

CompletedOBSERVATIONAL

Enrollment

333

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

December 1, 2017

Study Completion Date

December 1, 2017

Conditions

Prostate Cancer

Interventions

DRUG

Leuprorelin acetate

Leuplin PRO for Injection Kit 22.5 mg

Trial Locations (1)

Unknown

Takeda Selected Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT03209492 - "Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for Prostate Cancer" | Biotech Hunter | Biotech Hunter